News

Japan is currently facing an unprecedented surge in cases of streptococcal toxic shock syndrome (STSS), a severe and often fatal bacterial infection.

New research offers clues to susceptibility for the antiviral as the CDC updates the public on 2 strains circulating globally.

Experts emphasize prevalent waterborne illnesses and offer preventive advice for the summer season.

In response to evolving data on SARS-CoV-2 strains and rising COVID-19 cases, the FDA advises vaccine manufacturers to explore incorporating the KP2 strain into the upcoming 2024-2025 COVID-19 vaccine formula.

Overcoming “RSV identity crisis,” Moderna announced data for its investigational mRNA-1083 vaccine, BWC0977 effort to target drug-resistant pathogens, and more this week from Contagion.

Bruce Jones, PharmD, FIDSA, BCPS offered clinical considerations for patient dosing and clinical management strategies associated with concurrent therapy.

Bruce Jones, PharmD, FIDSA, BCPS provides commentary on treating challenging patients with comorbidities such as type 2 diabetes, higher BMI, and advanced age.

Leveraging Evie Ring technology, the collaboration seeks to enhance understanding and develop strategies for managing these illnesses.

A recently published secondary analysis sought to evaluate the risk of MACE in those patients who received one or two doses of the COVID-19 following acute coronary syndromes.

A study points to inpatients who were 50 years and older with the respiratory illness suffering from heart-related complications with the largest number of them having acute heart failure. 

With no observed mortality or adverse outcomes, this research sheds light on effective treatments for combating the pandemic in younger populations.

BWC0977 has strong potential to effectively target the priority pathogens needed to address public health concerns.

In the fourth and final episode, the clinicians speak of the need for greater uptake of the RSV vaccines, overcoming an "RSV identity crisis," and the potential ancillary benefit of reducing bacterial infections.

Our experts discuss the potential subgroups who might benefit from the vaccines and their safety profiles.

In part 2 of a 4-part series, clinicians discuss the efficacy, and the mechanism of action of the approved RSV vaccines, including the newly approved Moderna vaccine, mRNA 1345 (mRESVIA).

This is the first in a series of discussions between medical peers around RSV vaccines and specifically the newly approved Moderna RSV vaccine for seniors.

Brii Biosciences presented new data from Phase 2 trials for chronic hepatitis B at EASL Congress 2024, revealing insights into the efficacy of BRII-179 as botha combined therapy and an additional treatment.

Presented at DDW 2024 by Ken Blount, the effectiveness of live biotherapeutic products in treating recurrent C difficile infections (rCDI), offering insights into microbiota alteration and prospects for management.

Exact estimates of hospitalization and fatality rates for SARS-CoV-2 are rare among populations without previous exposure, particularly within demographic subgroups.

Seres is selling their microbiota product to Nestlé and expects to make a smooth transition as they already have an existing partnership.

Innovative approach across opioid treatment programs bridges geographical barriers, achieving cure rates, and unlocking health benefits for underserved populations.

The company announced data this morning for its investigational mRNA-1083 vaccine and plans to continue collecting data and working towards submitting a Biological License Application (BLA) for it.

Purportedly higher sepsis mortality in safety-net hospitals reflects less a difference in acute care than opportunities to discharge to hospice.

Historically, pneumococcal vaccination in adults has been reserved for those at heightened risk, with adults bearing the cost compared to free childhood vaccinations.

The federal agency’s decision expands the vaccine’s eligibility to people 50 years of age and older, making it the first one for this age group.

A newly published study suggests that a 15-day regimen, while safe, did not statistically separate from a placebo comparator group in main outcomes for PASC of SARS-CoV-2 infection.

FDA VRBPAC recommends protection against JN1 for the fall COVID-19 vaccines, a multidrug-resistant form of gonorrhea gives cause for concern, piperacillin-tazobactam shown to have higher mortality than cefepime for sepsis, and more this week from Contagion.

This man was the first person globally to have been diagnosed with influenza A(H5N2).